Literature DB >> 3796606

High mutation rate of a spleen necrosis virus-based retrovirus vector.

J P Dougherty, H M Temin.   

Abstract

Spleen necrosis virus (SNV) is an avian retrovirus that efficiently infects some mammalian cells (e.g., dog and rat cells). We constructed an SNV-based vector, which contains less than 1 kilobase (kb) of the retrovirus sequence, and a number of derivatives containing selectable markers. We obtained high-titer virus stocks, over 10(6) transforming units per ml, with a vector whose genomic RNA consists of 1,850 bases (full-length SNV RNA is 7.7 kb). We also studied two vectors that both carry two genes which should be expressed from a single promoter, one gene from unspliced mRNA and the other gene from spliced mRNA. In one vector, both genes were efficiently expressed as expected. However, in the other vector, expression of the gene 3' to the splice acceptor was inhibited. When we selected for expression of the 3' gene is this latter case, we found that the resistant cells contained mutant proviruses in which the 3' gene could be expressed. Furthermore, we found that mutations were generated during a single round of virus replication (provirus to provirus) at a rate of approximately 0.5% mutations per cycle.

Entities:  

Mesh:

Year:  1986        PMID: 3796606      PMCID: PMC367221          DOI: 10.1128/mcb.6.12.4387-4395.1986

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  35 in total

1.  A restriction enzyme cleavage map of Tn5 and location of a region encoding neomycin resistance.

Authors:  R A Jorgensen; S J Rothstein; W S Reznikoff
Journal:  Mol Gen Genet       Date:  1979

2.  Spliced early mRNAs of simian virus 40.

Authors:  A J Berk; P A Sharp
Journal:  Proc Natl Acad Sci U S A       Date:  1978-03       Impact factor: 11.205

3.  Mapping of RNA by a modification of the Berk-Sharp procedure: the 5' termini of 15 S beta-globin mRNA precursor and mature 10 s beta-globin mRNA have identical map coordinates.

Authors:  R F Weaver; C Weissmann
Journal:  Nucleic Acids Res       Date:  1979-11-10       Impact factor: 16.971

4.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

5.  Construction and isolation of a transmissible retrovirus containing the src gene of Harvey murine sarcoma virus and the thymidine kinase gene of herpes simplex virus type 1.

Authors:  C M Wei; M Gibson; P G Spear; E M Scolnick
Journal:  J Virol       Date:  1981-09       Impact factor: 5.103

6.  Variation in avian retrovirus genomes.

Authors:  J M Coffin; P N Tsichlis; C S Barker; S Voynow; H L Robinson
Journal:  Ann N Y Acad Sci       Date:  1980       Impact factor: 5.691

7.  Loss of intervening sequences in genomic mouse alpha-globin DNA inserted in an infectious retrovirus vector.

Authors:  K Shimotohno; H M Temin
Journal:  Nature       Date:  1982-09-16       Impact factor: 49.962

8.  Spontaneous changes in nucleotide sequence in proviruses of spleen necrosis virus, an avian retrovirus.

Authors:  J J O'Rear; H M Temin
Journal:  Proc Natl Acad Sci U S A       Date:  1982-02       Impact factor: 11.205

9.  Replication of reticuloendotheliosis viruses in cell culture: acute infection.

Authors:  H M Temin; V K Kassner
Journal:  J Virol       Date:  1974-02       Impact factor: 5.103

10.  Unstable beta-globin mRNA in mRNA-deficient beta o thalassemia.

Authors:  L E Maquat; A J Kinniburgh; E A Rachmilewitz; J Ross
Journal:  Cell       Date:  1981-12       Impact factor: 41.582

View more
  75 in total

1.  Most retroviral recombinations occur during minus-strand DNA synthesis.

Authors:  J Zhang; L Y Tang; T Li; Y Ma; C M Sapp
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Mutations in the v-Rel transactivation domain indicate altered phosphorylation and identify a subset of NF-kappaB-regulated cell death inhibitors important for v-Rel transforming activity.

Authors:  Béatrice Rayet; Yongjun Fan; Céline Gélinas
Journal:  Mol Cell Biol       Date:  2003-03       Impact factor: 4.272

3.  Direct determination of the point mutation rate of a murine retrovirus.

Authors:  R J Monk; F G Malik; D Stokesberry; L H Evans
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

4.  Unusually high frequency of reconstitution of long terminal repeats in U3-minus retrovirus vectors by DNA recombination or gene conversion.

Authors:  P Olson; H M Temin; R Dornburg
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

5.  Exon trapping: a genetic screen to identify candidate transcribed sequences in cloned mammalian genomic DNA.

Authors:  G M Duyk; S W Kim; R M Myers; D R Cox
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

6.  Oncogenic transformation by vrel requires an amino-terminal activation domain.

Authors:  J Kamens; P Richardson; G Mosialos; R Brent; T Gilmore
Journal:  Mol Cell Biol       Date:  1990-06       Impact factor: 4.272

7.  Poorly expressed endogenous ecotropic provirus of DBA/2 mice encodes a mutant Pr65gag protein that is not myristylated.

Authors:  N G Copeland; N A Jenkins; B Nexø; A M Schultz; A Rein; T Mikkelsen; P Jørgensen
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

8.  The RxxRxRxxC motif conserved in all Rel/kappa B proteins is essential for the DNA-binding activity and redox regulation of the v-Rel oncoprotein.

Authors:  S Kumar; A B Rabson; C Gélinas
Journal:  Mol Cell Biol       Date:  1992-07       Impact factor: 4.272

9.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.

Authors:  L M Mansky; H M Temin
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

10.  Antisense suppression of skeletal muscle myosin light chain-1 biosynthesis impairs myofibrillogenesis in cultured myotubes.

Authors:  R Nawrotzki; D A Fischman; T Mikawa
Journal:  J Muscle Res Cell Motil       Date:  1995-02       Impact factor: 2.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.